In the Western population, approximately 70 to 90% of “triple-negative” breast cancers (ER-, PR-, HER2-) express basal markers, resulting in the triple-negative subtype commonly used as a surrogate marker for the basal-like subtype[1,4,8,18,29-37]. Here, ERBB2 is linked to breast cancer.